Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: Relationship to HER2/neu expression in human and mouse

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Khalil, Sara ^a   Tan, Grace A ^a   Giri, Dilip D ^b   Zhou, Xi Kathy ^a   Howe, Louise R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; WNT PROTEIN;

ADULT; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; BREAST; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CANCER INVASION; CELL JUNCTION; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SCORING SYSTEM; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR VOLUME; AGED; ANIMAL; GENE EXPRESSION; METABOLISM; MIDDLE AGED; PROTO ONCOGENE;

MUS;

AGED; ANIMALS; BETA CATENIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MIDDLE AGED; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; WNT PROTEINS;

EID: 84863352083     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033421     Document Type: Article

References (72)

1. Cadigan KM, Peifer M, (2009) Wnt signaling from development to disease: insights from model systems. Cold Spring Harb Perspect Biol 1: a002881.
2. Nusse R, (2008) Wnt signaling and stem cell control. Cell Res 18: 523-527.
3. Reya T, Clevers H, (2005) Wnt signalling in stem cells and cancer. Nature 434: 843-850.
4. Howe LR, Brown AMC, (2004) Wnt signaling and breast cancer. Cancer Biol Ther 3: 36-41.
5. Smalley MJ, Dale TC, (2001) Wnt signaling and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 6: 37-52.
6. Nusse R, van Ooyen A, Cox D, Fung YK, Varmus H, (1984) Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 307: 131-136.
7. Nusse R, Varmus HE, (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31: 99-109.
8. Peters G, Brookes S, Smith R, Dickson C, (1983) Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell 33: 369-377.
9. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE, (1988) Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55: 619-625.
10. Giles RH, van Es JH, Clevers H, (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24.
11. Polakis P, (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851.
12. Candidus S, Bischoff P, Becker KF, Hofler H, (1996) No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res 56: 49-52.
13. Furuuchi K, Tada M, Yamada H, Kataoka A, Furuuchi N, et al. (2000) Somatic mutations of the APC gene in primary breast cancers. Am J Pathol 156: 1997-2005.
14. Jonsson M, Borg A, Nilbert M, Andersson T, (2000) Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer 36: 242-248.
15. Kashiwaba M, Tamura G, Ishida M, (1994) Aberrations of the APC gene in primary breast carcinoma. J Cancer Res Clin Oncol 120: 727-731.
16. Schlosshauer PW, Brown SA, Eisinger K, Yan Q, Guglielminetti ER, et al. (2000) APC truncation and increased beta-catenin levels in a human breast cancer cell line. Carcinogenesis 21: 1453-1456.
17. Sorlie T, Bukholm I, Borresen-Dale AL, (1998) Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no. 179. Online. Hum Mutat 12: 215.
18. Webster MT, Rozycka M, Sara E, Davis E, Smalley M, et al. (2000) Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 28: 443-453.
19. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, et al. (2011) beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231.
20. Abraham SC, Reynolds C, Lee JH, Montgomery EA, Baisden BL, et al. (2002) Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol 33: 39-46.
21. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG, (2008) Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 14: 4038-4044.
22. Gonzalez MA, Pinder SE, Wencyk PM, Bell JA, Elston CW, et al. (1999) An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol 187: 523-529.
23. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97: 4262-4266.
24. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP, (2001) Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 3: 793-801.
25. Bukholm IR, Bukholm G, Nesland JM, (2001) Coexpression of cyclin A and beta-catenin and survival in breast cancer patients. Int J Cancer 94: 148-149.
26. Prasad CP, Gupta SD, Rath G, Ralhan R, (2007) Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncology 73: 112-117.
27. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, et al. (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176: 2911-2920.
28. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, et al. (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 19: 301-309.
29. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, Keramopoulos A, Davaris PS, et al. (2001) Expression patterns of beta-catenin in in situ and invasive breast cancer. Eur J Surg Oncol 27: 31-36.
30. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, et al. (2004) beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 100: 2084-2092.
31. Logullo AF, Nonogaki S, Pasini FS, Osorio CA, Soares FA, et al. (2010) Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol Rep 23: 313-320.
32. Bertolo C, Guerrero D, Vicente F, Cordoba A, Esteller M, et al. (2008) Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol 130: 414-424.
33. Hoschuetzky H, Aberle H, Kemler R, (1994) Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 127: 1375-1380.
34. Hazan RB, Norton L, (1998) The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 273: 9078-9084.
35. Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, et al. (2001) Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. Cancer Res 61: 1671-1677.
36. Adam L, Vadlamudi RK, McCrea P, Kumar R, (2001) Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta-catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem 276: 28443-28450.
37. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, et al. (2002) ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 277: 22692-22698.
38. Lu Z, Ghosh S, Wang Z, Hunter T, (2003) Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499-515.
39. Graham NA, Asthagiri AR, (2004) Epidermal growth factor-mediated T-cell factor/lymphoid enhancer factor transcriptional activity is essential but not sufficient for cell cycle progression in nontransformed mammary epithelial cells. J Biol Chem 279: 23517-23524.
40. Wang K, Ma Q, Ren Y, He J, Zhang Y, et al. (2007) Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. Oncol Rep 17: 89-96.
41. Civenni G, Holbro T, Hynes NE, (2003) Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep 4: 166-171.
42. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE, (2007) Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 9: R63.
43. Baker R, Kent CV, Silbermann RA, Hassell JA, Young LJ, et al. (2010) Pea3 transcription factors and Wnt1-induced mouse mammary neoplasia. PLoS One 5: e8854.
44. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145.
45. Siegel PM, Ryan ED, Cardiff RD, Muller WJ, (1999) Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. Embo J 18: 2149-2164.
46. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, et al. (2005) HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65: 10113-10119.
47. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, et al. (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22: 1172-1183.
48. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, et al. (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22: 1184-1193.
49. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, et al. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89: 10578-10582.
50. Siegel PM, Dankort DL, Hardy WR, Muller WJ, (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14: 7068-7077.
51. Kurpios NA, MacNeil L, Shepherd TG, Gludish DW, Giacomelli AO, et al. (2009) The Pea3 Ets transcription factor regulates differentiation of multipotent progenitor cells during mammary gland development. Dev Biol 325: 106-121.
52. Hothorn T, Bretz F, Westfall P, (2008) Simultaneous inference in general parametric models. Biom J 50: 346-363.
53. Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, et al. (2010) CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One 5: e8979.
54. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, et al. (2006) Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66: 5487-5494.
55. Zschiesche W, Schonborn I, Behrens J, Herrenknecht K, Hartveit F, et al. (1997) Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17: 561-567.
56. Berx G, Van Roy F, (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293.
57. Birchmeier W, Behrens J, (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198: 11-26.
58. Prosperi JR, Goss KH, (2010) A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets 11: 1074-1088.
59. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, et al. (2009) MMTV-Wnt1 and-DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS ONE 4: e4537.
60. Badders NM, Goel S, Clark RJ, Klos KS, Kim S, et al. (2009) The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. PLoS ONE 4: e6594.
61. Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, et al. (2009) The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS ONE 4: e5813.
62. Lindvall C, Bu W, Williams BO, Li Y, (2007) Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev 3: 157-168.
63. Zeng YA, Nusse R, (2011) Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell 6: 568-577.
64. Clapper ML, Coudry J, Chang WC, (2004) beta-catenin-mediated signaling: a molecular target for early chemopreventive intervention. Mutat Res 555: 97-105.
65. Sormunen RT, Leong AS, Vaaraniemi JP, Fernando SS, Eskelinen SM, (1999) Immunolocalization of the fodrin, E-cadherin, and beta-catenin adhesion complex in infiltrating ductal carcinoma of the breast-comparison with an in vitro model. J Pathol 187: 416-423.
66. Olmeda D, Castel S, Vilaro S, Cano A, (2003) Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol Biol Cell 14: 2844-2860.
67. McCartney BM, McEwen DG, Grevengoed E, Maddox P, Bejsovec A, et al. (2001) Drosophila APC2 and Armadillo participate in tethering mitotic spindles to cortical actin. Nat Cell Biol 3: 933-938.
68. Kaplan DD, Meigs TE, Kelly P, Casey PJ, (2004) Identification of a role for beta-catenin in the establishment of a bipolar mitotic spindle. J Biol Chem 279: 10829-10832.
69. Bahmanyar S, Kaplan DD, Deluca JG, Giddings TH Jr, O'Toole ET, et al. (2008) beta-Catenin is a Nek2 substrate involved in centrosome separation. Genes Dev 22: 91-105.
70. Bartkova J, Barnes DM, Millis RR, Gullick WJ, (1990) Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 21: 1164-1167.
71. Park K, Han S, Kim HJ, Kim J, Shin E, (2006) HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48: 702-707.
72. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA, (1990) Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma-a detailed morphological analysis. J Pathol 161: 7-14.